Homocysteine in Chronic Kidney Disease

Advances in Clinical Chemistry

Volumn 72, Issue , 2015, Pages 77-106

  Ostrakhovitch, Elena A ^a   Tabibzadeh, Siamak ^a  

^a Frontiers in Bioscience Research Institute in Aging and Cancer   (United States)

Author keywords

Cysteine targeted oxidation thiolation; Homocysteine; Hydrogen sulfide; Kidney; Podocytes; Protein posttranslation modification; Redox regulation; Sulfhydration; Transsulfuration pathway

Indexed keywords

HOMOCYSTEINE;

BLOOD; CHRONIC KIDNEY FAILURE; HUMAN; HYPERHOMOCYSTEINEMIA; METHYLATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS;

HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; METHYLATION; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84939863413     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2015.07.002     Document Type: Chapter

References (198)

1. Refsum H., Ueland P.M., Nygard O., Vollset S.E. Homocysteine and cardiovascular disease. Annu. Rev. Med. 1998, 49:31-62.
2. Selhub J. Homocysteine metabolism. Annu. Rev. Nutr. 1999, 19:217-246.
3. Dudman N.P., Guo X.W., Gordon R.B., Dawson P.A., Wilcken D.E. Human homocysteine catabolism: three major pathways and their relevance to development of arterial occlusive disease. J. Nutr. 1996, 126:1295S-1300S.
4. House J.D., Brosnan M.E., Brosnan J.T. Characterization of homocysteine metabolism in the rat kidney. Biochem. J. 1997, 328(Pt. 1):287-292.
5. House J.D., Brosnan M.E., Brosnan J.T. Renal uptake and excretion of homocysteine in rats with acute hyperhomocysteinemia. Kidney Int. 1998, 54:1601-1607.
6. Ventura P., Panini R., Pasini M.C., Scarpetta G., Salvioli G. N-Acetyl-cysteine reduces homocysteine plasma levels after single intravenous administration by increasing thiols urinary excretion. Pharmacol. Res. 1999, 40:345-350.
7. Foreman J.W., Wald H., Blumberg G., Pepe L.M., Segal S. Homocystine uptake in isolated rat renal cortical tubules. Metabolism 1982, 31:613-619.
8. Friedman A.N., Bostom A.G., Selhub J., Levey A.S., Rosenberg I.H. The kidney and homocysteine metabolism. J. Am. Soc. Nephrol. 2001, 12:2181-2189.
9. Tessari P., Coracina A., Kiwanuka E., Vedovato M., Vettore M., Valerio A., Zaramella M., Garibotto G. Effects of insulin on methionine and homocysteine kinetics in type 2 diabetes with nephropathy. Diabetes 2005, 54:2968-2976.
10. Bostom A.G., Shemin D., Gohh R.Y., Beaulieu A.J., Jacques P.F., Dworkin L., Selhub J. Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. Transplantation 2000, 69:2128-2131.
11. Kang S.S., Wong P.W., Malinow M.R. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu. Rev. Nutr. 1992, 12:279-298.
12. Rodriguez W.E., Tyagi N., Joshua I.G., Passmore J.C., Fleming J.T., Falcone J.C., Tyagi S.C. Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus. Am. J. Physiol. Renal Physiol. 2006, 291:F694-F701.
13. Rodriguez W.E., Sen U., Tyagi N., Kumar M., Carneal G., Aggrawal D., Newsome J., Tyagi S.C. PPAR gamma agonist normalizes glomerular filtration rate, tissue levels of homocysteine, and attenuates endothelial-myocyte uncoupling in alloxan induced diabetic mice. Int. J. Biol. Sci. 2008, 4:236-244.
14. Sen U., Rodriguez W.E., Tyagi N., Kumar M., Kundu S., Tyagi S.C. Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E1205-E1212.
15. Jhee K.H., Kruger W.D. The role of cystathionine beta-synthase in homocysteine metabolism. Antioxid. Redox Signal. 2005, 7:813-822.
16. Sen U., Pushpakumar S.B., Amin M.A., Tyagi S.C. Homocysteine in renovascular complications: hydrogen sulfide is a modulator and plausible anaerobic ATP generator. Nitric Oxide 2014, 41:27-37.
17. Modis K., Bos E.M., Calzia E., van Goor H., Coletta C., Papapetropoulos A., Hellmich M.R., Radermacher P., Bouillaud F., Szabo C. Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part II. Pathophysiological and therapeutic aspects. Br. J. Pharmacol. 2014, 171:2123-2146.
18. Szabo C., Ransy C., Modis K., Andriamihaja M., Murghes B., Coletta C., Olah G., Yanagi K., Bouillaud F. Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms. Br. J. Pharmacol. 2014, 171:2099-2122.
19. Olson K.R. A practical look at the chemistry and biology of hydrogen sulfide. Antioxid. Redox Signal. 2012, 17:32-44.
20. Finkelstein J.D. Methionine metabolism in mammals. J. Nutr. Biochem. 1990, 1:228-237.
21. Sturman J.A., Rassin D.K., Gaull G.E. Relation of three enzymes of transsulphuration to the concentration of cystathionine in various regions of monkey brain. J. Neurochem. 1970, 17:1117-1119.
22. Beltowski J. Hypoxia in the renal medulla: implications for hydrogen sulfide signaling. J. Pharmacol. Exp. Ther. 2010, 334:358-363.
23. Neuhofer W., Beck F.X. Survival in hostile environments: strategies of renal medullary cells. Physiology (Bethesda) 2006, 21:171-180.
24. Malinowska J., Kolodziejczyk J., Olas B. The disturbance of hemostasis induced by hyperhomocysteinemia; the role of antioxidants. Acta Biochim. Pol. 2012, 59:185-194.
25. Gupta S., Wang L., Hua X., Krijt J., Kozich V., Kruger W.D. Cystathionine beta-synthase p.S466L mutation causes hyperhomocysteinemia in mice. Hum. Mutat. 2008, 29:1048-1054.
26. Wald R., Quinn R.R., Luo J., Li P., Scales D.C., Mamdani M.M., Ray J.G. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 2009, 302:1179-1185.
27. Waikar S.S., Winkelmayer W.C. Chronic on acute renal failure: long-term implications of severe acute kidney injury. JAMA 2009, 302:1227-1229.
28. Prathapasinghe G.A., Siow Y.L., Karmin O. Detrimental role of homocysteine in renal ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. 2007, 292:F1354-F1363.
29. Wang P., Isaak C.K., Siow Y.L., Karmin O. Downregulation of cystathionine beta-synthase and cystathionine gamma-lyase expression stimulates inflammation in kidney ischemia-reperfusion injury. Physiol. Rep. 2014, 2:e12251.
30. Xu Z., Prathapasinghe G., Wu N., Hwang S.Y., Siow Y.L., Karmin O. Ischemia-reperfusion reduces cystathionine-beta-synthase-mediated hydrogen sulfide generation in the kidney. Am. J. Physiol. Renal Physiol. 2009, 297:F27-F35.
31. Xia M., Chen L., Muh R.W., Li P.L., Li N. Production and actions of hydrogen sulfide, a novel gaseous bioactive substance, in the kidneys. J. Pharmacol. Exp. Ther. 2009, 329:1056-1062.
32. Herrmann W., Obeid R. Homocysteine: a biomarker in neurodegenerative diseases. Clin. Chem. Lab. Med. 2011, 49:435-441.
33. Petras M., Tatarkova Z., Kovalska M., Mokra D., Dobrota D., Lehotsky J., Drgova A. Hyperhomocysteinemia as a risk factor for the neuronal system disorders. J. Physiol. Pharmacol. 2014, 65:15-23.
34. Yi F., Zhang A.Y., Li N., Muh R.W., Fillet M., Renert A.F., Li P.L. Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats. Kidney Int. 2006, 70:88-96.
35. Jacobsen D.W. Hyperhomocysteinemia and oxidative stress: time for a reality check?. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1182-1184.
36. Sibrian-Vazquez M., Escobedo J.O., Lim S., Samoei G.K., Strongin R.M. Homocystamides promote free-radical and oxidative damage to proteins. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:551-554.
37. Lang D., Kredan M.B., Moat S.J., Hussain S.A., Powell C.A., Bellamy M.F., Powers H.J., Lewis M.J. Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta: role for superoxide anions. Arterioscler. Thromb. Vasc. Biol. 2000, 20:422-427.
38. Sipkens J.A., Hahn N., van den Brand C.S., Meischl C., Cillessen S.A., Smith D.E., Juffermans L.J., Musters R.J., Roos D., Jakobs C., Blom H.J., Smulders Y.M., Krijnen P.A., Stehouwer C.D., Rauwerda J.A., van Hinsbergh V.W., Niessen H.W. Homocysteine-induced apoptosis in endothelial cells coincides with nuclear NOX2 and peri-nuclear NOX4 activity. Cell Biochem. Biophys. 2013, 67:341-352.
39. Zhang C., Xia M., Boini K.M., Li C.X., Abais J.M., Li X.X., Laperle L.A., Li P.L. Epithelial-to-mesenchymal transition in podocytes mediated by activation of NADPH oxidase in hyperhomocysteinemia. Pflugers Arch. 2011, 462:455-467.
40. Yang Z.Z., Zou A.P. Homocysteine enhances TIMP-1 expression and cell proliferation associated with NADH oxidase in rat mesangial cells. Kidney Int. 2003, 63:1012-1020.
41. Yi F., Zhang A.Y., Janscha J.L., Li P.L., Zou A.P. Homocysteine activates NADH/NADPH oxidase through ceramide-stimulated Rac GTPase activity in rat mesangial cells. Kidney Int. 2004, 66:1977-1987.
42. Shah S.V. The role of reactive oxygen metabolites in glomerular disease. Annu. Rev. Physiol. 1995, 57:245-262.
43. Yao K. Effects of several unusual sulfur-containing amino acids on rat liver cystathionine-gamma-lyase. Physiol. Chem. Phys. 1975, 7:401-408.
44. Sen U., Basu P., Abe O.A., Givvimani S., Tyagi N., Metreveli N., Shah K.S., Passmore J.C., Tyagi S.C. Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. Am. J. Physiol. Renal Physiol. 2009, 297:F410-F419.
45. Sen U., Munjal C., Qipshidze N., Abe O., Gargoum R., Tyagi S.C. Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis. Am. J. Nephrol. 2010, 31:442-455.
46. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J. Clin. Invest. 1996, 98:5-7.
47. Stamler J.S., Osborne J.A., Jaraki O., Rabbani L.E., Mullins M., Singel D., Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J. Clin. Invest. 1993, 91:308-318.
48. Postea O., Krotz F., Henger A., Keller C., Weiss N. Stereospecific and redox-sensitive increase in monocyte adhesion to endothelial cells by homocysteine. Arterioscler. Thromb. Vasc. Biol. 2006, 26:508-513.
49. Fischer P.A., Dominguez G.N., Cuniberti L.A., Martinez V., Werba J.P., Ramirez A.J., Masnatta L.D. Hyperhomocysteinemia induces renal hemodynamic dysfunction: is nitric oxide involved?. J. Am. Soc. Nephrol. 2003, 14:653-660.
50. Yi F., dos Santos E.A., Xia M., Chen Q.Z., Li P.L., Li N. Podocyte injury and glomerulosclerosis in hyperhomocysteinemic rats. Am. J. Nephrol. 2007, 27:262-268.
51. Zhang C., Hu J.J., Xia M., Boini K.M., Brimson C., Li P.L. Redox signaling via lipid raft clustering in homocysteine-induced injury of podocytes. Biochim. Biophys. Acta 2010, 1803:482-491.
52. Nagase M., Shibata S., Yoshida S., Nagase T., Gotoda T., Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006, 47:1084-1093.
53. Pavenstadt H., Kriz W., Kretzler M. Cell biology of the glomerular podocyte. Physiol. Rev. 2003, 83:253-307.
54. Yi F., Jin S., Zhang F., Xia M., Bao J.X., Hu J., Poklis J.L., Li P.L. Formation of lipid raft redox signalling platforms in glomerular endothelial cells: an early event of homocysteine-induced glomerular injury. J. Cell. Mol. Med. 2009, 13:3303-3314.
55. Himmelfarb J., McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int. 2001, 60:358-363.
56. Terawaki H., Yoshimura K., Hasegawa T., Matsuyama Y., Negawa T., Yamada K., Matsushima M., Nakayama M., Hosoya T., Era S. Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int. 2004, 66:1988-1993.
57. Era S., Hamaguchi T., Sogami M., Kuwata K., Suzuki E., Miura K., Kawai K., Kitazawa Y., Okabe H., Noma A., et al. Further studies on the resolution of human mercapt- and nonmercaptalbumin and on human serum albumin in the elderly by high-performance liquid chromatography. Int. J. Pept. Protein Res. 1988, 31:435-442.
58. Himmelfarb J., McMonagle E., McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int. 2000, 58:2571-2578.
59. Kao M.P., Ang D.S., Pall A., Struthers A.D. Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options. J. Hum. Hypertens. 2010, 24:1-8.
60. Regazzoni L., Del Vecchio L., Altomare A., Yeum K.J., Cusi D., Locatelli F., Carini M., Aldini G. Human serum albumin cysteinylation is increased in end stage renal disease patients and reduced by hemodialysis: mass spectrometry studies. Free Radic. Res. 2013, 47:172-180.
61. Matsuyama Y., Terawaki H., Terada T., Era S. Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease. Clin. Exp. Nephrol. 2009, 13:308-315.
62. Wratten M.L., Sereni L., Tetta C. Oxidation of albumin is enhanced in the presence of uremic toxins. Ren. Fail. 2001, 23:563-571.
63. Mera K., Anraku M., Kitamura K., Nakajou K., Maruyama T., Otagiri M. The structure and function of oxidized albumin in hemodialysis patients: its role in elevated oxidative stress via neutrophil burst. Biochem. Biophys. Res. Commun. 2005, 334:1322-1328.
64. Suzuki Y., Suda K., Matsuyama Y., Era S., Soejima A. Close relationship between redox state of human serum albumin and serum cysteine levels in non-diabetic CKD patients with various degrees of renal function. Clin. Nephrol. 2014, 82:320-325.
65. Choi S.T., Kim J.S., Song J.S. Elevated serum homocysteine levels were not correlated with serum uric acid levels, but with decreased renal function in gouty patients. J. Korean Med. Sci. 2014, 29:788-792.
66. van Guldener C., Stam F., Stehouwer C.D. Homocysteine metabolism in renal failure. Kidney Int. Suppl. 2001, 78:S234-S237.
67. Sengupta S., Wehbe C., Majors A.K., Ketterer M.E., DiBello P.M., Jacobsen D.W. Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation. J. Biol. Chem. 2001, 276:46896-46904.
68. Sengupta S., Chen H., Togawa T., DiBello P.M., Majors A.K., Budy B., Ketterer M.E., Jacobsen D.W. Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J. Biol. Chem. 2001, 276:30111-30117.
69. Lacinski M., Skorupski W., Cieslinski A., Sokolowska J., Trzeciak W.H., Jakubowski H. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans. Cell. Mol. Biol. (Noisy-le-Grand) 2004, 50:885-893.
70. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell. Mol. Life Sci. 2004, 61:470-487.
71. Glowacki R., Jakubowski H. Cross-talk between Cys34 and lysine residues in human serum albumin revealed by N-homocysteinylation. J. Biol. Chem. 2004, 279:10864-10871.
72. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 1999, 13:2277-2283.
73. Perla-Kajan J., Marczak L., Kajan L., Skowronek P., Twardowski T., Jakubowski H. Modification by homocysteine thiolactone affects redox status of cytochrome C. Biochemistry 2007, 46:6225-6231.
74. Jakubowski H. Proofreading in vivo: editing of homocysteine by methionyl-tRNA synthetase in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:4504-4508.
75. Jakubowski H. Homocysteine is a protein amino acid in humans. Implications for homocysteine-linked disease. J. Biol. Chem. 2002, 277:30425-30428.
76. Jakubowski H. Pathophysiological consequences of homocysteine excess. J. Nutr. 2006, 136:1741S-1749S.
77. Chwatko G., Jakubowski H. Urinary excretion of homocysteine-thiolactone in humans. Clin. Chem. 2005, 51:408-415.
78. Chwatko G., Jakubowski H. The determination of homocysteine-thiolactone in human plasma. Anal. Biochem. 2005, 337:271-277.
79. Perla-Kajan J., Twardowski T., Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids 2007, 32:561-572.
80. Sikora M., Marczak L., Kubalska J., Graban A., Jakubowski H. Identification of N-homocysteinylation sites in plasma proteins. Amino Acids 2014, 46:235-244.
81. Bossenmeyer-Pourie C., Pourie G., Koziel V., Helle D., Jeannesson E., Gueant J.L., Beck B. Early methyl donor deficiency produces severe gastritis in mothers and offspring through N-homocysteinylation of cytoskeleton proteins, cellular stress, and inflammation. FASEB J. 2013, 27:2185-2197.
82. Perla-Kajan J., Jakubowski H. Paraoxonase 1 and homocysteine metabolism. Amino Acids 2012, 43:1405-1417.
83. Yang S., Yang Y., Yu P., Yang J., Jiang X., Villar V.A., Sibley D.R., Jose P.A., Zeng C. Dopamine D1 and D5 receptors differentially regulate oxidative stress through paraoxonase 2 in kidney cells. Free Radic. Res. 2015, 49:397-410.
84. Perla-Kajan J., Jakubowski H. Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J. 2010, 24:931-936.
85. Paragh G., Seres I., Balogh Z., Varga Z., Karpati I., Matyus J., Ujhelyi L., Kakuk G. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron 1998, 80:166-170.
86. Gugliucci A., Lunceford N., Kinugasa E., Ogata H., Schulze J., Kimura S. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Clin. Chim. Acta 2007, 384:105-112.
87. Gugliucci A., Kotani K., Kimura S. Paraoxonase 1 in chronic kidney failure. J. Lipids 2012, 2012:726048.
88. Dantoine T.F., Debord J., Charmes J.P., Merle L., Marquet P., Lachatre G., Leroux-Robert C. Decrease of serum paraoxonase activity in chronic renal failure. J. Am. Soc. Nephrol. 1998, 9:2082-2088.
89. Kappelle P.J., Bijzet J., Hazenberg B.P., Dullaart R.P. Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome. Arch. Med. Res. 2011, 42:219-225.
90. Varga E., Seres I., Harangi M., Sztanek F., Asztalos L., Locsey L., Borbas B., Szegedi J., Karpati I., Paragh G. Serum cystatin C is a determinant of paraoxonase activity in hemodialyzed and renal transplanted patients. Dis. Markers 2009, 26:141-148.
91. Suszynska-Zajczyk J., Sikora M., Jakubowski H. Paraoxonase 1 deficiency and hyperhomocysteinemia alter the expression of mouse kidney proteins involved in renal disease. Mol. Genet. Metab. 2014, 113:200-206.
92. Finkelstein J.D. The metabolism of homocysteine: pathways and regulation. Eur. J. Pediatr. 1998, 157(Suppl. 2):S40-S44.
93. Shlomi T., Rabinowitz J.D. Metabolism: cancer mistunes methylation. Nat. Chem. Biol. 2013, 9:293-294.
94. Perna A.F., Ingrosso D., De Santo N.G., Galletti P., Zappia V. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney Int. 1995, 47:247-253.
95. Perna A.F., Ingrosso D., Violetti E., Luciano M.G., Sepe I., Lanza D., Capasso R., Ascione E., Raiola I., Lombardi C., Stenvinkel P., Massy Z., De Santo N.G. Hyperhomocysteinemia in uremia-a red flag in a disrupted circuit. Semin. Dial. 2009, 22:351-356.
96. Esse R., Rocha M.S., Barroso M., Florindo C., Teerlink T., Kok R.M., Smulders Y.M., Rivera I., Leandro P., Koolwijk P., Castro R., Blom H.J., de Almeida I.T. Protein arginine methylation is more prone to inhibition by S-adenosylhomocysteine than DNA methylation in vascular endothelial cells. PLoS One 2013, 8:e55483.
97. Perna A.F., Ingrosso D., Zappia V., Galletti P., Capasso G., De Santo N.G. Enzymatic methyl esterification of erythrocyte membrane proteins is impaired in chronic renal failure. Evidence for high levels of the natural inhibitor S-adenosylhomocysteine. J. Clin. Invest. 1993, 91:2497-2503.
98. Loehrer F.M., Angst C.P., Brunner F.P., Haefeli W.E., Fowler B. Evidence for disturbed S-adenosylmethionine: S-adenosylhomocysteine ratio in patients with end-stage renal failure: a cause for disturbed methylation reactions?. Nephrol. Dial. Transplant. 1998, 13:656-661.
99. Ingrosso D., Cimmino A., Perna A.F., Masella L., De Santo N.G., De Bonis M.L., Vacca M., D'Esposito M., D'Urso M., Galletti P., Zappia V. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003, 361:1693-1699.
100. Stenvinkel P., Karimi M., Johansson S., Axelsson J., Suliman M., Lindholm B., Heimburger O., Barany P., Alvestrand A., Nordfors L., Qureshi A.R., Ekstrom T.J., Schalling M. Impact of inflammation on epigenetic DNA methylation-a novel risk factor for cardiovascular disease?. J. Intern. Med. 2007, 261:488-499.
101. Akchiche N., Bossenmeyer-Pourie C., Kerek R., Martin N., Pourie G., Koziel V., Helle D., Alberto J.M., Ortiou S., Camadro J.M., Leger T., Gueant J.L., Daval J.L. Homocysteinylation of neuronal proteins contributes to folate deficiency-associated alterations of differentiation, vesicular transport, and plasticity in hippocampal neuronal cells. FASEB J. 2012, 26:3980-3992.
102. Hsu C.Y., Sun C.Y., Lee C.C., Wu I.W., Hsu H.J., Wu M.S. Global DNA methylation not increased in chronic hemodialysis patients: a case-control study. Ren. Fail. 2012, 34:1195-1199.
103. Bromberg A., Levine J., Belmaker R., Agam G. Hyperhomocysteinemia does not affect global DNA methylation and nicotinamide N-methyltransferase expression in mice. J. Psychopharmacol. 2011, 25:976-981.
104. Xu L., Chen J., Gao J., Yu H., Yang P. Crosstalk of homocysteinylation, methylation and acetylation on histone H3. Analyst 2015, 140:3057-3063.
105. Zhang D., Sun X., Liu J., Xie X., Cui W., Zhu Y. Homocysteine accelerates senescence of endothelial cells via DNA hypomethylation of human telomerase reverse transcriptase. Arterioscler. Thromb. Vasc. Biol. 2015, 35:71-78.
106. Zhang D.H., Wen X.M., Zhang L., Cui W. DNA methylation of human telomerase reverse transcriptase associated with leukocyte telomere length shortening in hyperhomocysteinemia-type hypertension in humans and in a rat model. Circ. J. 2014, 78:1915-1923.
107. Kloda K., Domanski L., Kwiatkowska E., Borowiecka E., Safranow K., Drozd A., Ciechanowicz A., Maciejewska-Karlowska A., Sawczuk M., Pawlik A., Ciechanowski K. hTERT, BICD1 and chromosome 18 polymorphisms associated with telomere length affect kidney allograft function after transplantation. Kidney Blood Press. Res. 2015, 40:111-120.
108. Jones D.P. Redefining oxidative stress. Antioxid. Redox Signal. 2006, 8:1865-1879.
109. Schafer F.Q., Buettner G.R. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 2001, 30:1191-1212.
110. Pihl A., Eldjarn L., Bremer J. On the mode of action of X-ray protective agents. III. The enzymatic reduction of disulfides. J. Biol. Chem. 1957, 227:339-345.
111. Crawhall J.C., Segal S. The intracellular ratio of cysteine and cystine in various tissues. Biochem. J. 1967, 105:891-896.
112. Rodrigues S.D., Batista G.B., Ingberman M., Pecoits-Filho R., Nakao L.S. Plasma cysteine/cystine reduction potential correlates with plasma creatinine levels in chronic kidney disease. Blood Purif. 2012, 34:231-237.
113. Gahl W.A., Thoene J.G., Schneider J.A. Cystinosis. N. Engl. J. Med. 2002, 347:111-121.
114. Wilmer M.J., Willems P.H., Verkaart S., Visch H.J., de Graaf-Hess A., Blom H.J., Monnens L.A., van den Heuvel L.P., Levtchenko E.N. Cystine dimethylester model of cystinosis: still reliable?. Pediatr. Res. 2007, 62:151-155.
115. Sansanwal P., Yen B., Gahl W.A., Ma Y., Ying L., Wong L.J., Sarwal M.M. Mitochondrial autophagy promotes cellular injury in nephropathic cystinosis. J. Am. Soc. Nephrol. 2010, 21:272-283.
116. Sumayao R., McEvoy B., Martin-Martin N., McMorrow T., Newsholme P. Cystine dimethylester loading promotes oxidative stress and a reduction in ATP independent of lysosomal cystine accumulation in a human proximal tubular epithelial cell line. Exp. Physiol. 2013, 98:1505-1517.
117. Bellomo F., Corallini S., Pastore A., Palma A., Laurenzi C., Emma F., Taranta A. Modulation of CTNS gene expression by intracellular thiols. Free Radic. Biol. Med. 2010, 48:865-872.
118. Vendemiale G., Guerrieri F., Grattagliano I., Didonna D., Muolo L., Altomare E. Mitochondrial oxidative phosphorylation and intracellular glutathione compartmentation during rat liver regeneration. Hepatology 1995, 21:1450-1454.
119. Brunetti M., Terracina L., Timio M., Saronio P., Capodicasa E. Plasma sulfate concentration and hyperhomocysteinemia in hemodialysis patients. J. Nephrol. 2001, 14:27-31.
120. Chu F., Ward N.E., O'Brian C.A. PKC isozyme S-cysteinylation by cystine stimulates the pro-apoptotic isozyme PKC delta and inactivates the oncogenic isozyme PKC epsilon. Carcinogenesis 2003, 24:317-325.
121. Auclair J.R., Brodkin H.R., D'Aquino J.A., Petsko G.A., Ringe D., Agar J.N. Structural consequences of cysteinylation of Cu/Zn-superoxide dismutase. Biochemistry 2013, 52:6145-6150.
122. Davies K.J., Goldberg A.L. Proteins damaged by oxygen radicals are rapidly degraded in extracts of red blood cells. J. Biol. Chem. 1987, 262:8227-8234.
123. Fujiwara N., Nakano M., Kato S., Yoshihara D., Ookawara T., Eguchi H., Taniguchi N., Suzuki K. Oxidative modification to cysteine sulfonic acid of Cys111 in human copper-zinc superoxide dismutase. J. Biol. Chem. 2007, 282:35933-35944.
124. Franco R., Schoneveld O.J., Pappa A., Panayiotidis M.I. The central role of glutathione in the pathophysiology of human diseases. Arch. Physiol. Biochem. 2007, 113:234-258.
125. Lash L.H. Role of glutathione transport processes in kidney function. Toxicol. Appl. Pharmacol. 2005, 204:329-342.
126. Aw T.Y. Cellular redox: a modulator of intestinal epithelial cell proliferation. News Physiol. Sci. 2003, 18:201-204.
127. Hansen S.H., Grunnet N. Taurine, glutathione and bioenergetics. Adv. Exp. Med. Biol. 2013, 776:3-12.
128. Pastore A., Federici G., Bertini E., Piemonte F. Analysis of glutathione: implication in redox and detoxification. Clin. Chim. Acta 2003, 333:19-39.
129. Canestrari F., Buoncristiani U., Galli F., Giorgini A., Albertini M.C., Carobi C., Pascucci M., Bossu M. Redox state, antioxidative activity and lipid peroxidation in erythrocytes and plasma of chronic ambulatory peritoneal dialysis patients. Clin. Chim. Acta 1995, 234:127-136.
130. Apeland T., Kristensen O., Mansoor M.A. The aminothiol redox status in haemodialysis patients does not improve with folate therapy. Scand. J. Clin. Lab. Invest. 2009, 69:265-271.
131. Canestrari F., Galli F., Giorgini A., Albertini M.C., Galiotta P., Pascucci M., Bossu M. Erythrocyte redox state in uremic anemia: effects of hemodialysis and relevance of glutathione metabolism. Acta Haematol. 1994, 91:187-193.
132. Galli F., Rovidati S., Benedetti S., Buoncristiani U., Covarelli C., Floridi A., Canestrari F. Overexpression of erythrocyte glutathione S-transferase in uremia and dialysis. Clin. Chem. 1999, 45:1781-1788.
133. Dessi M., Noce A., Dawood K.F., Galli F., Taccone-Gallucci M., Fabrini R., Bocedi A., Massoud R., Fucci G., Pastore A., Manca di Villahermosa S., Zingaretti V., Federici G., Ricci G. Erythrocyte glutathione transferase: a potential new biomarker in chronic kidney diseases which correlates with plasma homocysteine. Amino Acids 2012, 43:347-354.
134. Granqvist A., Nilsson U.A., Ebefors K., Haraldsson B., Nystrom J. Impaired glomerular and tubular antioxidative defense mechanisms in nephrotic syndrome. Am. J. Physiol. Renal Physiol. 2010, 299:F898-F904.
135. Dalle-Donne I., Milzani A., Gagliano N., Colombo R., Giustarini D., Rossi R. Molecular mechanisms and potential clinical significance of S-glutathionylation. Antioxid. Redox Signal. 2008, 10:445-473.
136. Dalle-Donne I., Rossi R., Colombo G., Giustarini D., Milzani A. Protein S-glutathionylation: a regulatory device from bacteria to humans. Trends Biochem. Sci. 2009, 34:85-96.
137. Mieyal J.J., Gallogly M.M., Qanungo S., Sabens E.A., Shelton M.D. Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid. Redox Signal. 2008, 10:1941-1988.
138. Townsend D.M. S-glutathionylation: indicator of cell stress and regulator of the unfolded protein response. Mol. Interv. 2007, 7:313-324.
139. Rinna A., Torres M., Forman H.J. Stimulation of the alveolar macrophage respiratory burst by ADP causes selective glutathionylation of protein tyrosine phosphatase 1B. Free Radic. Biol. Med. 2006, 41:86-91.
140. Huang Z., Pinto J.T., Deng H., Richie J.P. Inhibition of caspase-3 activity and activation by protein glutathionylation. Biochem. Pharmacol. 2008, 75:2234-2244.
141. Hondorp E.R., Matthews R.G. Oxidative stress inactivates cobalamin-independent methionine synthase (MetE) in Escherichia coli. PLoS Biol. 2004, 2:e336.
142. Casagrande S., Bonetto V., Fratelli M., Gianazza E., Eberini I., Massignan T., Salmona M., Chang G., Holmgren A., Ghezzi P. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:9745-9749.
143. Michelet L., Zaffagnini M., Marchand C., Collin V., Decottignies P., Tsan P., Lancelin J.M., Trost P., Miginiac-Maslow M., Noctor G., Lemaire S.D. Glutathionylation of chloroplast thioredoxin f is a redox signaling mechanism in plants. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16478-16483.
144. Niu W.N., Yadav P.K., Adamec J., Banerjee R. S-glutathionylation enhances human cystathionine beta-synthase activity under oxidative stress conditions. Antioxid. Redox Signal. 2015, 22:350-361.
145. Salzano S., Checconi P., Hanschmann E.M., Lillig C.H., Bowler L.D., Chan P., Vaudry D., Mengozzi M., Coppo L., Sacre S., Atkuri K.R., Sahaf B., Herzenberg L.A., Herzenberg L.A., Mullen L., Ghezzi P. Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:12157-12162.
146. Kondo N., Nakamura H., Masutani H., Yodoi J. Redox regulation of human thioredoxin network. Antioxid. Redox Signal. 2006, 8:1881-1890.
147. Holmgren A. Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid. Redox Signal. 2000, 2:811-820.
148. Kasuno K., Shirakawa K., Yoshida H., Mori K., Kimura H., Takahashi N., Nobukawa Y., Shigemi K., Tanabe S., Yamada N., Koshiji T., Nogaki F., Kusano H., Ono T., Uno K., Nakamura H., Yodoi J., Muso E., Iwano M. Renal redox dysregulation in AKI: application for oxidative stress marker of AKI. Am. J. Physiol. Renal Physiol. 2014, 307:F1342-F1351.
149. Tsuchikura S., Shoji T., Shimomura N., Kakiya R., Emoto M., Koyama H., Ishimura E., Inaba M., Nishizawa Y. Serum C-reactive protein and thioredoxin levels in subjects with mildly reduced glomerular filtration rate. BMC Nephrol. 2010, 11:7.
150. Tobino K., Muso E., Iwasaki Y., Yonemoto S., Kasuno K., Tsukamoto T., Nakamura H., Tomino Y. Gender- and disease-specific urinary thioredoxin in chronic kidney disease patients with or without type 2 diabetic nephropathy. Nephrology (Carlton) 2015, 20:368-374.
151. Kagi J.H., Schaffer A. Biochemistry of metallothionein. Biochemistry 1988, 27:8509-8515.
152. Romero-Isart N., Vasak M. Advances in the structure and chemistry of metallothioneins. J. Inorg. Biochem. 2002, 88:388-396.
153. Davis S.R., Cousins R.J. Metallothionein expression in animals: a physiological perspective on function. J. Nutr. 2000, 130:1085-1088.
154. Kagi J.H., Vallee B.L. The role of zinc in alcohol dehydrogenase. V. The effect of metal-binding agents on the structure of the yeast alcohol dehydrogenase molecule. J. Biol. Chem. 1960, 235:3188-3192.
155. Kumari M.V., Hiramatsu M., Ebadi M. Free radical scavenging actions of metallothionein isoforms I and II. Free Radic. Res. 1998, 29:93-101.
156. Maret W., Vallee B.L. Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3478-3482.
157. Bell S.G., Vallee B.L. The metallothionein/thionein system: an oxidoreductive metabolic zinc link. Chembiochem 2009, 10:55-62.
158. Takahashi T., Itano Y., Noji S., Matsumoto K., Taga N., Mizukawa S., Toda N., Matsumi M., Morita K., Hirakawa M. Induction of renal metallothionein in rats with ischemic renal failure. Res. Commun. Mol. Pathol. Pharmacol. 2001, 110:147-160.
159. Kojima I., Tanaka T., Inagi R., Nishi H., Aburatani H., Kato H., Miyata T., Fujita T., Nangaku M. Metallothionein is upregulated by hypoxia and stabilizes hypoxia-inducible factor in the kidney. Kidney Int. 2009, 75:268-277.
160. Wu H., Zhou S., Kong L., Chen J., Feng W., Cai J., Miao L., Tan Y. Metallothionein deletion exacerbates intermittent hypoxia-induced renal injury in mice. Toxicol. Lett. 2015, 232:340-348.
161. Barbato J.C., Catanescu O., Murray K., DiBello P.M., Jacobsen D.W. Targeting of metallothionein by l-homocysteine: a novel mechanism for disruption of zinc and redox homeostasis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:49-54.
162. Glushchenko A.V., Jacobsen D.W. Molecular targeting of proteins by l-homocysteine: mechanistic implications for vascular disease. Antioxid. Redox Signal. 2007, 9:1883-1898.
163. Liu S.X., Fabisiak J.P., Tyurin V.A., Borisenko G.G., Pitt B.R., Lazo J.S., Kagan V.E. Reconstitution of apo-superoxide dismutase by nitric oxide-induced copper transfer from metallothioneins. Chem. Res. Toxicol. 2000, 13:922-931.
164. Blaschke F., Bruemmer D., Law R.E. Egr-1 is a major vascular pathogenic transcription factor in atherosclerosis and restenosis. Rev. Endocr. Metab. Disord. 2004, 5:249-254.
165. Khachigian L.M. Early growth response-1 in cardiovascular pathobiology. Circ. Res. 2006, 98:186-191.
166. Tonelli M., Wiebe N., Hemmelgarn B., Klarenbach S., Field C., Manns B., Thadhani R., Gill J. Trace elements in hemodialysis patients: a systematic review and meta-analysis. BMC Med. 2009, 7:25.
167. Pakfetrat M., Shahroodi J.R., Zolgadr A.A., Larie H.A., Nikoo M.H., Malekmakan L. Effects of zinc supplement on plasma homocysteine level in end-stage renal disease patients: a double-blind randomized clinical trial. Biol. Trace Elem. Res. 2013, 153:11-15.
168. Upchurch G.R., Welch G.N., Fabian A.J., Freedman J.E., Johnson J.L., Keaney J.F., Loscalzo J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J. Biol. Chem. 1997, 272:17012-17017.
169. Handy D.E., Zhang Y., Loscalzo J. Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J. Biol. Chem. 2005, 280:15518-15525.
170. 2S protects against methionine-induced oxidative stress in brain endothelial cells. Antioxid. Redox Signal. 2009, 11:25-33.
171. Kabil O., Banerjee R. Redox biochemistry of hydrogen sulfide. J. Biol. Chem. 2010, 285:21903-21907.
172. Dombkowski R.A., Russell M.J., Olson K.R. Hydrogen sulfide as an endogenous regulator of vascular smooth muscle tone in trout. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 286:R678-R685.
173. Finkel T. From sulfenylation to sulfhydration: what a thiolate needs to tolerate. Sci. Signal. 2012, 5:e10.
174. 2S signals through protein S-sulfhydration. Sci. Signal. 2009, 2:ra72.
175. Paul B.D., Snyder S.H. H(2)S signalling through protein sulfhydration and beyond. Nat. Rev. Mol. Cell Biol. 2012, 13:499-507.
176. Poole L.B., Nelson K.J. Discovering mechanisms of signaling-mediated cysteine oxidation. Curr. Opin. Chem. Biol. 2008, 12:18-24.
177. Klomsiri C., Karplus P.A., Poole L.B. Cysteine-based redox switches in enzymes. Antioxid. Redox Signal. 2011, 14:1065-1077.
178. 2S-induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response. Sci. Signal. 2011, 4:ra86.
179. Heneberg P. Reactive nitrogen species and hydrogen sulfide as regulators of protein tyrosine phosphatase activity. Antioxid. Redox Signal. 2014, 20:2191-2209.
180. Zhao K., Ju Y., Li S., Altaany Z., Wang R., Yang G. S-sulfhydration of MEK1 leads to PARP-1 activation and DNA damage repair. EMBO Rep. 2014, 15:792-800.
181. Ingram A.J., Krepinsky J.C., James L., Austin R.C., Tang D., Salapatek A.M., Thai K., Scholey J.W. Activation of mesangial cell MAPK in response to homocysteine. Kidney Int. 2004, 66:733-745.
182. Xie Z.Z., Shi M.M., Xie L., Wu Z.Y., Li G., Hua F., Bian J.S. Sulfhydration of p66Shc at cysteine59 mediates the antioxidant effect of hydrogen sulfide. Antioxid. Redox Signal. 2014, 21:2531-2542.
183. Toohey J.I. Sulfur signaling: is the agent sulfide or sulfane?. Anal. Biochem. 2011, 413:1-7.
184. Sen N., Paul B.D., Gadalla M.M., Mustafa A.K., Sen T., Xu R., Kim S., Snyder S.H. Hydrogen sulfide-linked sulfhydration of NF-kappaB mediates its antiapoptotic actions. Mol. Cell 2012, 45:13-24.
185. Mustafa A.K., Sikka G., Gazi S.K., Steppan J., Jung S.M., Bhunia A.K., Barodka V.M., Gazi F.K., Barrow R.K., Wang R., Amzel L.M., Berkowitz D.E., Snyder S.H. Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels. Circ. Res. 2011, 109:1259-1268.
186. Mir S., Sen T., Sen N. Cytokine-induced GAPDH sulfhydration affects PSD95 degradation and memory. Mol. Cell 2014, 56:786-795.
187. Shinkai Y., Abiko Y., Ida T., Miura T., Kakehashi H., Ishii I., Nishida M., Sawa T., Akaike T., Kumagai Y. Reactive sulfur species-mediated activation of the Keap1-Nrf2 pathway by 1,2-naphthoquinone through sulfenic acids formation under oxidative stress. Chem. Res. Toxicol. 2015, 28:838-847.
188. Yang G., Zhao K., Ju Y., Mani S., Cao Q., Puukila S., Khaper N., Wu L., Wang R. Hydrogen sulfide protects against cellular senescence via S-sulfhydration of Keap1 and activation of Nrf2. Antioxid. Redox Signal. 2013, 18:1906-1919.
189. Kimura H. Hydrogen sulfide and polysulfides as signaling molecules. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2015, 91:131-159.
190. Kimura H. Signaling molecules: hydrogen sulfide and polysulfide. Antioxid. Redox Signal. 2015, 22:362-376.
191. 2S-derived signaling molecules in rat brain. FASEB J. 2013, 27:2451-2457.
192. 2S to protein thiol oxidation. Antioxid. Redox Signal. 2013, 19:1749-1765.
193. Koike S., Ogasawara Y., Shibuya N., Kimura H., Ishii K. Polysulfide exerts a protective effect against cytotoxicity caused by t-buthylhydroperoxide through Nrf2 signaling in neuroblastoma cells. FEBS Lett. 2013, 587:3548-3555.
194. Holleman-Wiberg's Inorganic Chemistry 2001, Academic Press. E. Wiberg (Ed.).
195. Kimura H. Hydrogen sulfide and polysulfides as biological mediators. Molecules 2014, 19:16146-16157.
196. Yamanishi T., Tuboi S. The mechanism of the l-cystine cleavage reaction catalyzed by rat liver gamma-cystathionase. J. Biochem. 1981, 89:1913-1921.
197. Ida T., Sawa T., Ihara H., Tsuchiya Y., Watanabe Y., Kumagai Y., Suematsu M., Motohashi H., Fujii S., Matsunaga T., Yamamoto M., Ono K., Devarie-Baez N.O., Xian M., Fukuto J.M., Akaike T. Reactive cysteine persulfides and S-polythiolation regulate oxidative stress and redox signaling. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:7606-7611.
198. Wilmer M.J., Kluijtmans L.A., van der Velden T.J., Willems P.H., Scheffer P.G., Masereeuw R., Monnens L.A., van den Heuvel L.P., Levtchenko E.N. Cysteamine restores glutathione redox status in cultured cystinotic proximal tubular epithelial cells. Biochim. Biophys. Acta 2011, 1812:643-651.